Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, acute erythroid leukemia, acute megakaryoblastic leukemia, acute myeloid leukemia, anemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with ring sideroblasts, myelodysplastic syndrome with single lineage dysplasia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm	Active, not recruiting	Phase 1 / Phase 2	2026-08-07		NCT00392353

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
National Cancer Institute (NCI)	3015

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Montefiore Medical Center - Moses Campus	The Bronx	United States	219
Montefiore Medical Center-Weiler Hospital	The Bronx	United States	109
Mount Sinai Hospital	New York	United States	225
North Shore University Hospital	Manhasset	United States	70
NYP/Weill Cornell Medical Center	New York	United States	128
University of Chicago Comprehensive Cancer Center	Chicago	United States	273
University of Maryland/Greenebaum Cancer Center	Baltimore	United States	152